脐带间充质干细胞治疗失代偿期肝硬化的肝组织炎性调控机制研究

间充质干细胞（MSC）治疗重症肝病已在动物实验和临床研究中取得了较好疗效，但其治疗机制研究目前主要是基于体外实验和动物模型，且主要为非肝脏疾病动物模型，缺少在人体水平研究MSC治疗重症肝病的相关机制。本课题将在脐带来源的MSC（UC-MSC）治疗失代偿期肝硬化临床研究的基础上，应用DNAscope/RNAscope、单细胞基因测序、遗传学、Luminex、以及流式细胞术，从人体水平探讨UC-MSC调控肝组织免疫（炎性）环境，促进损伤修复和再生，以及UC-MSC在肝组织中的定植并分化为肝细胞的可能性。本研究首次从人体水平阐述UC-MSC治疗失代偿期肝硬化的相关机制,为进一步临床应用提供依据。

Mesenchymal stem cells (MSC) in the treatment of severe liver disease has achieved good efficacy in animal experiments and clinical studies, but its therapeutic mechanism is mainly based on in vitro experiments and animal models, and mainly non-liver disease animal models, lack of human studies on the relevant mechanism of MSC in the treatment for severe liver disease. On the basis of clinical trial with the treatment of umbilical cord MSC (UC-MSC) for decompensated liver cirrhosis, this study will investigate UC-MSC regulate liver tissue immune (inflammatory) environment, promote injury hepatocytes repair and hepatocytes regeneration, and UC-MSC engraftment in the liver tissue and the possibility of UC-MSC differentiation into hepatocytes by application of technologies of DNAscope/RNAscope, single cell gene sequencing, genetics, Luminex, flow cytometry. This study is the first time to elucidate the mechanism of UC-MSC in the treatment of decompensated cirrhosis in in vivo, and to provide the basis for further clinical application.